Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
By J. Holzbeierlein, P. Lal, É. Latulippe, Alex Smith, J. Satagopan, Liying Zhang, C. Ryan, Steve Smith, H. Scher, P. Scardino and 2 more. American Journal of Pathology, 2004
602 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/1f005115879b6073eaa51bb58e0f95fab681306b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants (2011, unknown): “Prostate cancers progressing in the setting of castration maintain or reactivate the gene expression program regulated by the androgen receptor (AR) (27).”
- The Estrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer (2014, unknown): “2a ) 7,10-22 , 28-31 28-31 .”
- Increased survival with enzalutamide in prostate cancer after chemotherapy. (2012, unknown): “Fatigue 269 (34) 50 (6) 116 (29) 29 (7)”
- Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. (2008, background): “Besides the uptake and conversion of circulating adrenal androgens, prostate cancer metastases may also be capable of de novo androgen biosynthesis from cholesterol and/or progesterone precursors ( 19 ).”
- Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011, unknown): “Urinary tract infection 91 (12) 17 (2) 0 28 (7) 2 (<1) 0”
- Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy (2012, unknown): “Adverse event leading to death* 20 (4) 12 (2) Adverse event of grade 1–4 in ≥15% of patients in either group Fatigue 212 (39) 185 (34) Back pain 173 (32) 173 (32) Arthralgia 154 (28) 129 (24) Nausea 120 (22) 118 (22) Constipation 125 (23) 103 (19) Hot flush 121 (22) 98 (18) Diarrhea 117 (22) 96 (18)”
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008, background): “Sources include the adrenal glands or the tumor itself as a result of the upregulation of the genes involved in androgen synthesis.(15,16) Recognizing that some patients have higher testosterone levels despite continued androgen depletion with GnRH analog therapy, and that total testosterone levels ”
- Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. (2006, background): “Finally, another study that examined three cases of androgen ablation–resistant prostate cancer found increased expression of several enzymes mediating early steps in sterol biosynthesis (5).”
- Molecular genetics of prostate cancer: new prospects for old challenges. (2010, background): “…has been supported by expression profiling of tumors with and without neoadjuvant androgen ablation prior to radical prostatectomy, which showed that castration-resistant tumors displayed up-regulation of AR, androgen synthetic enzymes, and known AR target genes (Holzbeierlein et al. 2004).”